UCB (XBRU:UCB) Change In Payables And Accrued Expense : €0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is UCB Change In Payables And Accrued Expense?

UCB's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €0 Mil. It means UCB's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

UCB's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €0 Mil. It means UCB's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

UCB Change In Payables And Accrued Expense Historical Data

The historical data trend for UCB's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Change In Payables And Accrued Expense Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

UCB Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

UCB Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of UCB's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (XBRU:UCB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (XBRU:UCB) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (XBRU:UCB) Headlines

No Headlines